Opinion

Video

Single-Agent Immune Therapy in UC: The Need for More

Author(s):

Thomas Powles MBBS, MRCP, MD

Thomas Powles, MBBS, MRCP, MD, discusses how different trials have been used to study urothelial cancer (UC) treatments, including DANUBE, IMvigor130, and KEYNOTE-361, all of which are frontline, randomized, phase 3 studies that were unsuccessful. A trial that had better results involved nivolumab plus gemcitabine/cisplatin, due to patients being in better physical condition to withstand chemotherapy.

Related Videos
1 expert in this video
Janaki Neela Sharma, MD, University of Miami
Janaki Neela Sharma, MD, discusses CheckMate 901, and where nivolumab plus chemotherapy fits into the advanced urothelial cancer treatment paradigm.
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
Urothelial Cancer
November 16th 2024

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Gautier Marcq, MD
November 7th 2024

Padeliporfin VTP Maintains Robust Responses and is Safe in Low-Grade Upper-Tract Urothelial Cancer

Oncology Unplugged
July 24th 2024

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
November 2nd 2024

The OncFive: Top Oncology Articles for the Week of 10/27

Benjamin Herzberg, MD
October 29th 2024

IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC